Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Asterand’s Subsidiary BioSeek Extends Collaboration with Merck Serono

Published: Thursday, March 29, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
New three-year deal provides Merck Serono expanded access to BioSeek LLC’s BioMAP® platform.

BioSeek, LLC, a subsidiary of Asterand plc, a pioneer in the application of predictive human biology to drug discovery, has announced that it has signed a new, three-year collaboration agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

The new agreement extends and expands the companies’ previous three-year agreement from 2009.

Under the new research plan, BioSeek will expand the use of its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono.

Jack Davis, Chairman and Interim Chief Executive Officer of Asterand commented: “We highly value our long-standing relationship with Merck Serono. The studies carried out by BioSeek for Merck Serono over the past three years have demonstrated that BioMAP Platform can be used to reliably advance promising molecules through preclinical evaluation. Our scientists have worked closely and productively with the Merck Serono team, and we look forward to our continuing and expanding research with them.”

BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.

Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database.

Assessment with BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals
ToxCast high-throughput screening results using BioSeek’s BioMAP® human primary cell assay systems presented at society of toxicology.
Monday, March 19, 2012
BioSeek and EPA Expand ToxCast™ Contract
BioMAP® Systems technology to profile the biological effects of compounds in a second phase of the agency’s ToxCast™ program.
Monday, July 06, 2009
BioSeek Licenses Two Novel Anti-Inflammatory Peptides
The two peptides, licensed from Amylin Pharmaceuticals, were identified as candidates for development in ongoing research collaboration between the two companies.
Friday, November 14, 2008
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!